Pharma Tech

Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront

Aug 11, 2026, 8:49 AM

Read Full Article → Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront

Translate article text

Choose a language and wait for the translated text.

Jazz Pharmaceuticals is to acquire Actio Biosciences in a deal that includes an $820m upfront payment and up to $500m in additional contingent payments.